Platelet Immunobiology studies the pathogenic immune mechanisms responsible for autoimmune (e.g. Immune thrombocytopenia or ITP) and alloimmune (e.g. transfusion-induced) platelet disorders. In ITP, platelets are destructed by platelet-specific antibodies leading to bleeding in these patients. To date, platelet alloantigens are characterized by molecular biology techniques (e.g. PCR) since a single nucleotide polymorphisms in the platelet membrane proteins can result in specific platelet antigenicity. Anti-platelet antibodies are measured by various serology techniques (e.g. monoclonal antibody-specific immobilization of platelet antigens or MAIPA).
We promote basic and clinical research and aim to improve the current laboratory diagnostic tests for alloimmune platelet disorders (e.g. FNAIT) and human platelet antigens (HPA) nomenclature. We are interested in the various platelet serology and molecular biology techniques. When significant disparities are observed during quality controls, we regularly exchange (test) plasma/serum samples and materials among our members' laboratories and laboratory results are evaluated. We discuss the various standard methodologies for detection of anti-platelet antibodies. Also, we provide knowledge and training for our members and perform collaborative studies.
Our Chairpersons are Sentot Santoso and Nelson Tsuno.
We meet at ISBT congresses, organize training and various 'wet-bench' workshops. In these workshops the current technologies are being evaluated and standards are developed. Quality control is performed on serological, genotyping tests and current assays in use for the detection for platelet alloantibodies.
Topics covered in previous workshops include:
- detection of platelet alloantibodies for external quality control
- performing quantification test for anti-HPA-1a antibodies
- setting up protocols for detection of anti-platelet autoantibodies
- comparing the results of test serum or plasma by MAIPA
- HPA genotyping
All ISBT members interested in this field are able to join. Employees of pharmaceutical companies are allowed to attend the meetings; however, they cannot become a WP member nor participate in a workshop.
Some of the content is only accessible for ISBT-members. To join us, click here.
Fetal and Neonatal alloimmune thrombocytopenia (FNAIT) is a severe bleeding disorder affecting fetuses and newborns. Patients have low platelet counts due to antibodies specific for human platelet antigens inherited from the father. In severe cases, intracranial haemorrhage could occur.
The ISBT Working Party on Platelet Immunobiology has drafted an electronic survey on FNAIT therapy. The goal of the survey is to help clinicians in management of patients and improve FNAIT therapy globally and survey results will therefore be of great importance.
To participate, neonatologists /gynaecologists /obstetricians can click here (free). The survey does not take more than 10min and all participants will be informed of the results of the survey by email.
Contact: Gérald BERTRAND, French Blood Services of Brittany "EFS": gerald.bertrand@ efs.sante.fr
Thank you for your time.